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ABSTRACT
Background: Tumour hypoxia is associated with increased radioresistance and poor response to radio-
therapy. Pre-treatment assessment of tumour oxygenation could therefore give the possibility to tailor
the treatment by calculating the required boost dose needed to overcome the increased radioresist-
ance in hypoxic tumours. This study concerned the derivation of a non-linear conversion function
between the uptake of the hypoxia-PET tracer 18F-HX4 and oxygen partial pressure (pO2).
Material and methods: Building on previous experience with FMISO including experimental data on
tracer uptake and pO2, tracer-specific model parameters were derived for converting the normalised
HX4-uptake at the optimal imaging time point to pO2. The conversion function was implemented in a
Python-based computational platform utilising the scripting and the registration modules of the treat-
ment planning system RayStation. Subsequently, the conversion function was applied to determine the
pO2 in eight non-small-cell lung cancer (NSCLC) patients imaged with HX4-PET before the start of
radiotherapy. Automatic segmentation of hypoxic target volumes (HTVs) was then performed using
thresholds around 10mmHg. The HTVs were compared to sub-volumes segmented based on a
tumour-to-blood ratio (TBR) of 1.4 using the aortic arch as the reference oxygenated region. The boost
dose required to achieve 95% local control was then calculated based on the calibrated levels of hyp-
oxia, assuming inter-fraction reoxygenation due to changes in acute hypoxia but no overall improve-
ment of the oxygenation status.
Results: Using the developed conversion tool, HTVs could be obtained using pO2 a threshold of
10mmHg which were in agreement with the TBR segmentation. The dose levels required to the HTVs
to achieve local control were feasible, being around 70–80Gy in 24 fractions.
Conclusions: Non-linear conversion of tracer uptake to pO2 in NSCLC imaged with HX4-PET allows a
quantitative determination of the dose-boost needed to achieve a high probability of local control.
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Introduction
Tumour hypoxia is well-known as one of the most important
microenvironmental factors with respect to radiosensitivity
[1]. It has consequently been suggested that pretreatment
assessment of tumour oxygenation could improve treatment
outcome by targeting the radioresistant regions [2].
This could in theory be achieved by acquiring pretreatment
positron emission tomography (PET) images using hypoxia-
specific tracers. Such functional imaging could then be used
for the purpose of dose-painting, in which sub-volumes in
the tumour believed to be more radioresistant are given an
escalated dose compared to the rest of the target [3,4].
However, functional imaging could offer more information of
relevance than for target definition alone. Thus, if the tumour
oxygenation could be quantified based on PET imaging, the
dose required to overcome the increased radioresistance in
the hypoxic sub-volumes could be calculated, as opposed to
empirically escalating the dose within the constraints of nor-
mal tissue toxicity [3].
Several PET tracers are currently available for imaging
tumour hypoxia, the most used one in the clinic being
18F-FMISO [5]. Alternatives to 18F-FMISO have however been
tested, including 18F-HX4 [6], which was proposed to over-
come the slow clearance kinetics of 18F-FMISO and was inves-
tigated both in preclinical and clinical studies [6–11]. Both
these tracers belong to the nitromidazole family, and there-
fore it is expected that they have similar mechanisms for
binding to hypoxic cells. Nevertheless, the relationship
between the relative uptake of each tracer and the oxygen
partial pressure depends on the chemical composition of the
tracer and the biochemical processes through which
they bind to the hypoxic cells. This relationship has been
the concern for studies investigating the opportunity of tar-
geting hypoxia based on imaging with hypoxic tracers.
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The relationship for FMISO and FETA has been investigated a
few years back [12], but several other tracers have since
appeared. A recent study has investigated the general shape
of the relationship for F-HX4, but without determining the
parameters of the relationship [13].
The aim of this study was therefore to investigate the rela-
tionship between the uptake (at the time of optimal imaging
with respect to the tracer injection) and oxygen partial pres-
sure (pO2) for the hypoxia tracer
18F-HX4, and to derive the
parameters of the mathematical function describing this rela-
tionship based on previously performed measurements
of nitroimidazole uptake and pO2 [12]. In addition, the auto-
matic segmentation of the hypoxic target based on the con-
version of the 18F-HX4 uptake to pO2 was explored. The
feasibility of using the pO2 maps derived based on
18F-HX4
PET images for dose-painting was also investigated by calcu-
lating the doses to be prescribed for overcoming the hypoxic
radioresistance for a group of non-small-cell lung cancer
(NSCLC) patients.
Material and methods
Conversion function and derivation of its parameters
A model for converting 18F-FMISO uptake into oxygen partial
pressure (pO2) was previously proposed by Toma-Dasu et al.
[3,12], assuming a sigmoidal relationship between normalised
tracer uptake and pO2. The expression for the sigmoidal func-
tion is presented in Equation (1) and was chosen to describe
the inhibition of a chemical reaction. This is in line with the
uptake mechanism of nitroimidazole, which enters a cell
through diffusion and undergoes a first reduction to a poten-
tially reactive species. In the presence of oxygen, the reaction
is reversed by reoxidation and the tracer molecule can exit
the cell. For low concentrations of oxygen, however, further
reduction takes place that leads to the association of the
reduced nitroimidazole to intracellular components, effect-
ively trapping the tracer in the hypoxic cell [14]. The selective
uptake of nitroimidazoles in hypoxic cells can thus be
described as an inhibition of the reoxidation of the tracer
molecule. Thus, parameter A in Equation (1) is related to the
speed of the reaction in the absence of the inhibitor (i.e.,
molecular oxygen), while parameters B and C describe the
effect of the inhibition.
Uptake a:u:½  ¼ A B  pO2
C þ pO2 (1)
Numerical values have been reported for the parameters
A, B and C for 18F-FMISO in particular [12], but the general
mathematical expression in Equation (1) would be applicable
to any other tracer that is chemically similar to 18F-FMISO
with respect to the uptake mechanism. It should be noted
that the accumulation of a hypoxic tracer in tumours is sel-
dom given in absolute units, but as accumulation of activity
or standardised uptake value (SUV) of the injected tracer and
it is usually expressed as tumour to muscle ratio (TMR)
after normalising the uptake to that in muscle or a major
vessel as a substitute reference with good oxygenation.
Hypoxic volumes are then defined in practice using a suit-
able threshold for the TMR.
18F-HX4 and 18F-FMISO are both 2-nitroimidazole com-
pounds, and therefore the chemical process through which
the tracers are metabolised in a cell should be the same, as
described by the reduction and oxygen-dependent subse-
quent reoxidation of the R-NO2 molecule [14]. Consequently,
the general expression in Equation (1) describing the normal-
ised tracer uptake as a function of pO2 in the cell should
therefore be as applicable to 18F-HX4, as it is to 18F-FMISO.
Furthermore, the asymptotic behaviour of the conversion
functions should be the same for the two tracers. Since the
formation of the radical anion R-NO2
 cannot be reversed
in the absence of oxygen, the conversion function for 18F-
FMISO and that for 18F-HX4 should result in the same value
as the pO2 approaches zero and the uptake in Equation (1)
approaches A. Consequently, the parameter A was assumed
to be the same for both tracers. On the other extreme, for
very high values of pO2 corresponding to normoxic tissues,
Equation (1) can be simplified to Uptake  A B under the
assumption that pO2  C, which must also be the same for
both tracers. With A and A B fixed, B is also fixed and the
only parameter left to be determined for 18F-HX4 is C.
In Equation (1), the normalised uptake is defined as:
Uptake ¼ SUV
SUVref
 Uptakeref (2)
where SUVref is the standardised uptake value (SUV) in the
well-oxygenated reference region and:
Uptakeref ¼ A B  pO2ðrefÞC þ pO2ðrefÞ (3)
with pO2(ref) being the oxygen partial pressure in the
well-oxygenated reference region.
In the recent study by Lindblom et al. [13], the conversion
function in Equation (1) was able to identify hypoxic target
volumes (HTVs) of similar shape, size and location as the vol-
umes based on the segmentation method used in the cur-
rent practice in which a threshold of 1.4 relative to the
average SUV in the well-oxygenated reference region is
employed. Therefore, assuming pO2(ref)¼60mmHg as in a
well-oxygenated tissue, the final parameter for 18F-HX4 can
be found by solving:
1:4  A 60  B
60þ C
 
¼ A B  10
C þ 10 (4)
for C given that A¼ 10.9 and B¼ 10.7 as for 18F-
FMISO [12].
Application of the conversion function on NSCLC patient
data
The conversion function in Equation (1) with the set of
parameters derived for 18F-HX4 was applied on the imaging
data of eight non-small-cell lung cancer (NSCLC) patients
who have been imaged with 18F-HX4-PET before the start of
radiotherapy. Images were acquired four hours after the
injection of the tracer in line with pre-clinical [6] and clinical
[10] findings of the optimal time point for imaging
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with respect to the contrast. Further details of the imaging
protocol can be found in a previous publication by Even
et al. [11].
The construction of the three-dimensional pO2 maps
using the new parameters was done for each patient using
a scripting module implemented in a research version of
RayStation v4.6.100.4. Given the unknown ability of the
new conversion function to correctly identify HTVs with
respect to both their geometry and level of pO2, a range
of pO2 values around 10mmHg (8–12mmHg) were consid-
ered for the purpose of pO2-based segmentation. These
volumes were then compared with uptake-based volumes
segmented by considering an uptake threshold of 1.4 rela-
tive to a well-oxygenated reference region, representative
of the current clinical practice for segmentation in hypoxia-
PET images. The well-oxygenated reference region used for
the uptake-based segmentation as well as for the conver-
sion to pO2 was the aortic arch, which was delineated by
an experienced clinical oncologist. All thresholding and
segmentation was performed in RayStation, and only vol-
umes confined to the CTV were considered relevant for
the delineation of the HTV.
The HTVs based on the uptake and those based on
the conversion to pO2 were compared by calculating the
ratio of the intersection and the union of the
HTVuptake 1.4 and the HTVpO2 for a range of pO2 values
used for thresholding. The calculations were performed in
MATLAB R2016b.
Calculation of boost doses
Using the conversion function of the tracer uptake to pO2
would allow not only the identification of sub-target vol-
umes, but also the subsequent calculation of the boost dose
required in order to reach a desired level of tumour control
probability [15]. Thus, the HTV for the pO2 threshold resulting
in the highest overlap fraction was then used as a target vol-
ume for dose-painting, and the uniform boost dose required
to achieve 95% tumour control probability was calculated as
described by Toma-Dasu et al. [15,16]. According to the
model proposed by Toma-Dasu et al., the dose to a voxel at
the position r in the target that would ensure a given level
of tumour control probability (P) when delivered in n frac-
tions could be calculated as:
D̂ rð Þ ¼ n aðrÞ
2bðrÞ
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
1þ 1
n
4bðrÞ
a2ðrÞ ln
Vq
lnP
 s
 1
2
4
3
5 (5)
where a(r) and b(r) are parameters describing the cellular
radiosensitivity assuming the linear quadratic (LQ) model for
cell killing, and q is the clonogen density within the target
volume V. The a(r) and b(r) parameters depend on the pO2
as suggested in several other publications [12,15]. If the
inter-fraction reoxygenation resulting from the fluctuations in
acute hypoxia that can be expected to take place between
fractions [17] is taken into account, the heterogeneous dose
distribution resulting from applying Equation (5), could be
converted into a homogeneous dose boost to the HTV which
could counteract the effects of dose and radioresistance
heterogeneity [12,15]:
Dboost ¼
D
1 c2P rDD
 2h i (6)
where D and rD are respectively the average and standard
deviation of the heterogeneous dose distribution resulting
from applying Equation (5) and c is the slope of the dose
response curve. The following generic parameters were used
for calculations: a¼ 0.35Gy1, a/b¼ 10Gy, q¼ 109 cm3,
c¼ 4 [18,19]. For the purpose of comparison with the results
of Even et al. [11], n¼ 24 fractions was used for the dose cal-
culation, and a uniform density of clonogenic cells was
assumed.
Results
Conversion function and derivation of its parameters
Solving Equation (4) leads to two solutions for the C param-
eter, C¼ 111.5mmHg and C¼ 0.1mmHg. The larger C value
does not fulfil the condition of C 	 pO2 for high oxygen par-
tial pressures corresponding to normoxia. Furthermore, using
this C value will predict a normalised uptake in hypoxic tis-
sues that is at maximum 1.5 times higher than the uptake in
the reference region, providing little contrast between hyp-
oxia and normoxia. Hence, using this value for the parameter
C will not allow the practical identification of HTVs and
C¼ 111.5mmHg was discarded. The smaller value of
0.1mmHg however fulfils C 	 pO2 and results in a favour-
able discrimination between uptake values corresponding to
hypoxia and normoxia. An illustration of the relationship
between the tracer uptake and pO2 described by Equation
(1) using the lower value of the solution for the C parameter
(0.1mmHg) is shown in Figure 1.
The smaller C¼ 0.1mmHg was hence considered for the
conversion of normalised 18F-HX-PET uptake in the patient
cohort included in this study.
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Figure 1. Relationship between tracer uptake and tissue oxygenation for HX4
(green, lower curve), compared with the previously proposed corresponding
relationship for FMISO [12] (blue, upper curve).
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Application of the conversion function on NSCLC patient
data
The parameter set tested on the imaging data of the eight
NSCLC patients was thus (A, B, C)¼ (10.9, 10.7, 0.1mmHg).
With these parameters, HTVs that were in good agreement
with target volumes based on an uptake ratio of 1.4 to a
well-oxygenated reference region could be identified, with
the highest overlap for a threshold of 10mmHg for all
patients (Table 1).
This indicates that by using the conversion function for
18F-HX4 proposed in this paper, HTVs with geometric proper-
ties that are almost identical to those of the uptake-derived
boost volumes could be defined, as illustrated for patient 3
in Figure 2. In addition, this method provides a quantification
of the pO2 levels within the HTV (Figure 3), which is crucial
for the estimation of the boost dose required in hypoxia-
based dose-painting.
Calculation of boost doses
For the HTVs resulting in the highest relative overlap with
the uptake-based volumes, the uniform boost doses in 24
fractions calculated for a level of 95% tumour control prob-
ability are displayed in Table 2, assuming a uniform clonogen
density.
For all patients, the uniform prescription doses can be
regarded as clinically relevant with respect to the feasibility
study on dose escalation by Even et al. [11], which was based
on the same patient cohort as considered in the present
work.
Discussion
In this study, a novel non-linear conversion function between
normalised 18F-HX4 uptake and oxygen partial pressure has
been proposed. This function was derived independently
from the patient data on which it was subsequently applied
to identify HTVs for dose-painting.
The underlying assumption was that the same mathemat-
ical expression was valid for 18F-HX4 as for 18F-FMISO and
was based on the fact that both tracers are 2-nitroimidazoles
and hence the molecule (R-NO2) involved in the chemical
reaction leading (or not) to the retention is the same [14].
Previous studies have reported similar uptake patterns for
18F-HX4 and 18F-FMISO, supporting the assumption that the
two tracers are metabolised in a similar way [6,20]. The hyp-
oxic threshold is often referred to as oxygen partial pressure
levels between 2.5mmHg and 10mmHg [23]. In the present
study, 10mmHg was assumed to correspond to an uptake
ratio of 1.4 between the SUV in the hypoxic volume and the
well-oxygenated reference region. The HTVs resulting from
the conversion of normalised uptake to pO2 with highest
relative overlap with the uptake-based volumes were all
found for a threshold of 10mmHg. For all patients, the rela-
tive overlap with the uptake-based volumes was 96% or
higher. The good agreement between the uptake-based vol-
umes and the predicted threshold for defining the HTV based
on pO2 suggests that the assumptions behind the derivation
Table 1. The relative overlap between hypoxic target volumes based on relative uptake (HTVuptake1.4) and on the conversion to oxygen partial pressure
(HTVpO2). Numbers in bold refer to the maximum relative overlap found in each patient.
(HTVuptake1.4 \ HTVpO2)/(HTVuptake1.4 [ HTVpO2)
pO2 threshold
(mmHg) Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8
8.0 0.64 0.59 0.51 0.51 0.45 0.22 0.52 0.55
8.5 0.74 0.70 0.65 0.64 0.57 0.33 0.64 0.65
9.0 0.83 0.80 0.76 0.75 0.71 0.50 0.76 0.74
9.5 0.91 0.89 0.88 0.86 0.84 0.69 0.87 0.84
10.0 0.99 0.98 0.98 0.98 0.98 0.96 0.98 0.97
10.5 0.95 0.94 0.93 0.93 0.91 0.86 0.92 0.91
11.0 0.89 0.87 0.85 0.84 0.81 0.74 0.85 0.83
11.5 0.85 0.82 0.79 0.77 0.72 0.66 0.79 0.72
12.0 0.81 0.77 0.74 0.71 0.65 0.58 0.75 0.64
Figure 2. 18F-HX4-PET uptake (left) in patient 3, and the oxygen partial pressure map resulting from the conversion function (middle) with the CTV, shown in red.
To the right, the GTV is also shown in orange, containing the HTVpO2 (green) obtained with a threshold of 10mmHg and the HTVuptake (blue). The figure appears in
color in the online version of the article.
488 A. UREBA ET AL.
of the relationship between HX4 and pO2 is reasonable and
therefore further clinical validation is warranted.
The advantage of using a segmentation method based on
the conversion of the tracer uptake to pO2 instead of the
simple one based on a given threshold for the ratio of the
uptake in the tumour and in the well-oxygenated reference
region lays beyond the definition of the target. Thus, the
resulting pO2 distribution and the related radiation sensitivity
or resistance could be used for calculating the dose boost
needed to be prescribed and subsequently delivered to
achieve a certain level of control as reported in Table 2. It
should be noted that the underlying assumption in this study
has been that the clonogen density was the same in all vox-
els of the target volume, in line with the earlier proposal on
the topic [15]. This however might not be the case in all clin-
ical tumours and additional information would be required
on clonogen distribution in the tumour. In principle, such
information could be obtained with either FDG-PET [21] or
with DW-MRI [22]. It should be mentioned however that ana-
lysing the impact of the heterogeneous distribution of the
clonogenic cell density is beyond the scope of this paper as
the simultaneous use of information from multiple imaging
modalities is not straightforward [2] and therefore it is
planned to be investigated in a future study.
As previously mentioned, the clinical application of this
model, as that of any other model, has to be preceded by
validation against clinical outcome, once it will become
available. One approach could be by predicting the local
recurrence or local control based on the comparison
between the delivered dose distribution to the patients
presenting hypoxic targets and the calculated dose to be
delivered in order to achieve a high tumour control
probability.
Concluding, the present study presented a conversion
function between 18F-HX4-PET uptake and partial oxygen
pressure that could be used for the automatic identification
of HTVs. In addition, it was shown that the conversion func-
tion allows the quantification of the oxygen partial pressure
in these volumes, which could subsequently be used for the
purpose of hypoxia dose-painting based on 18F-HX4-PET
imaging following the validation of the model against the
clinical outcome.
Figure 3. Histograms of the oxygen partial pressure (pO2) in the hypoxic target volumes for all eight patients.
Table 2. The uniform prescribed boost dose in 24 fractions calculated for a tumor control probability (TCP) of 95%
according to Toma-Dasu et al. for the HTVs segmented using a threshold of 10mmHg [15,16].
Patient CTV (cm3) HTVpO2 (cm
3)
Uniform prescription dose, Dboost, in 24
fractions calculated for 95% TCP (Gy)
1 356.9 81.0 76.8
2 272.7 59.7 75.9
3 248.5 32.3 73.9
4 66.4 8.4 71.0
5 1105.3 50.6 75.3
6 85.5 4.5 68.3
7 427.4 101.8 76.5
8 128.7 10.6 71.9
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